Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo. Issue 8 (3rd August 2017)

• Record Type: Journal Article
• Authors: Patras, Laura; Sylvester, Bianca; Luput, Lavinia; Sesarman, Alina; Licarete, Emilia; Porfire, Alina; Muntean, Dana; Drotar, Denise Minerva; Rusu, Alexandra Doina; Nagy, Andras-Laszlo; Catoi, Cornel; Tomuta, Ioan; Vlase, Laurian; Banciu, Manuela; Achim, Marcela
• Is Part Of: Cancer biology & therapy. Volume 18:Issue 8(2017)
• Page Start: 616
• Page End: 626
• Publication Date: 2017-08-03
• Subjects: Colon carcinoma -- combination therapy -- liposomes -- prednisolone -- 5-fluorouracil -- angiogenesis -- inflammation; 616.99406
• DOI: 10.1080/15384047.2017.1345392
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: The antitumor efficacy of 5-fluorouracil (5-FU) in advanced colorectal cancer (CRC) is hindered not only by the low therapeutic index, but also by tumor cell resistance to this cytotoxic drug. Therefore, to enhance the 5-FU antitumor activity, the present research used a novel tumor-targeted therapy based on the co-administration of 5-FU encapsulated in long-circulating liposomes (LCL-5-FU) together with liposomal prednisolone phosphate (LCL-PLP), a formulation with known anti-angiogenic actions on C26 murine colon carcinoma cells . Thus, we assessed the in vivo effects of the combined liposomal drug therapy on C26 carcinoma growth as well as on the production of molecular markers with key roles in tumor development such as angiogenic, inflammatory, and oxidative stress molecules. To get further insight into the polarization state of tumor microenvironment after the treatment, we determined the IL-10/IL-12p70 ratio in tumors. Our results showed that combined liposomal drug therapy inhibited almost totally tumor growth and was superior as antitumor activity to both single liposomal drug therapies tested. The antitumor efficacy of the combined therapy was mainly related to the anti-angiogenic and anti-inflammatory actions on C26 carcinoma milieu, being favored by its controlling effect on intratumor oxidative stress and the skewing of polarization of tumor microenvironmental cells toward their antineoplastic phenotypes. Thus, our study unveils a promising treatment strategy for CRC that should be furthermore considered.